Skip to main
EVAX

EVAX Stock Forecast & Price Target

EVAX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evaxion AS has demonstrated a significant improvement in the prediction accuracy of its PIONEER AI model, with 81% of predicted neoantigens showing immunogenicity, an increase from the previous year's metrics. Additionally, the clinical data indicates a promising overall response rate (ORR) of 75% for EVX-01 in combination with pembrolizumab, surpassing earlier results and establishing a favorable safety profile compared to competitors in the field. The continuous success of these findings positions Evaxion to potentially attract strategic partnerships for late-stage development and commercialization, enhancing the outlook for the company's stock.

Bears say

Evaxion AS's stock experienced a negative reaction, despite a strong data update regarding its EVX-01 candidate, as investor expectations for a definitive assessment of EVX-01’s contribution to overall performance were not met. This suggests a disconnect between audience anticipation and the company’s ability to provide tangible results, potentially undermining investor confidence. Furthermore, the recommendation to accumulate EVAX on weakness indicates that market sentiment is currently cautious and uncertain about the company's immediate prospects.

EVAX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evaxion Biotech A/S (EVAX) Forecast

Analysts have given EVAX a Strong Buy based on their latest research and market trends.

According to 4 analysts, EVAX has a Strong Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evaxion Biotech A/S (EVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.